Sigmagos – Sigma1-receptor agonists as new therapeutic agents for neuro-degenerative

Sigma-receptors have been in the focus of drug discovery

for several years, being classified into two subtypes, sigma1- and sigma2-receptors. The sigma1-receptor is expressed in many different tissue types and is particularly concentrated in certain regions of the central nervous system. Therefore, it represents a new and different avenue in the possible pharmacological t reatment of brain related disorders. Several studies have shown that selective agonists of the sigma1-receptor affect higherordered brain functions such as learning and memory, cognition and mood. These studies indicate that sigma1- receptor agonists may exert therapeutic effects in dementia, depression, parkinsonism and neuropathic pain. Sigma ligands are also able to modulate endothelial cell proliferation and to control angiogenesis which makes them a promising target for oncology applications. Another area currently being investigated comprises the treatment of immune system disorders.

Weitere Informationen: PDF

PROvendis GmbH
Tel.: +49 (0)208/94105 10

Ansprechpartner
Dipl.-Ing. Alfred Schillert